Emergent Biosolutions Inc (EBS) Shares Bought by Legal & General Group Plc

Legal & General Group Plc boosted its stake in Emergent Biosolutions Inc (NYSE:EBS) by 4.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 70,378 shares of the biopharmaceutical company’s stock after purchasing an additional 3,045 shares during the period. Legal & General Group Plc owned about 0.17% of Emergent Biosolutions worth $2,845,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Aperio Group LLC increased its stake in shares of Emergent Biosolutions by 5.3% during the second quarter. Aperio Group LLC now owns 11,644 shares of the biopharmaceutical company’s stock worth $395,000 after buying an additional 589 shares during the period. Great West Life Assurance Co. Can boosted its position in Emergent Biosolutions by 6.8% during the 2nd quarter. Great West Life Assurance Co. Can now owns 50,912 shares of the biopharmaceutical company’s stock valued at $1,725,000 after purchasing an additional 3,230 shares during the period. Sei Investments Co. boosted its position in Emergent Biosolutions by 97,546.2% during the 2nd quarter. Sei Investments Co. now owns 38,082 shares of the biopharmaceutical company’s stock valued at $1,291,000 after purchasing an additional 38,043 shares during the period. Arizona State Retirement System boosted its position in Emergent Biosolutions by 0.6% during the 2nd quarter. Arizona State Retirement System now owns 18,160 shares of the biopharmaceutical company’s stock valued at $616,000 after purchasing an additional 100 shares during the period. Finally, First Trust Advisors LP boosted its position in Emergent Biosolutions by 169.2% during the 2nd quarter. First Trust Advisors LP now owns 53,149 shares of the biopharmaceutical company’s stock valued at $1,802,000 after purchasing an additional 33,403 shares during the period. Institutional investors and hedge funds own 88.44% of the company’s stock.

In related news, Director Zsolt Harsanyi sold 7,000 shares of Emergent Biosolutions stock in a transaction dated Thursday, December 7th. The stock was sold at an average price of $42.47, for a total transaction of $297,290.00. Following the completion of the transaction, the director now owns 37,077 shares in the company, valued at $1,574,660.19. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Daniel Abdun-Nabi sold 31,508 shares of Emergent Biosolutions stock in a transaction dated Friday, November 3rd. The stock was sold at an average price of $42.77, for a total value of $1,347,597.16. Following the transaction, the chief executive officer now owns 215,642 shares of the company’s stock, valued at approximately $9,223,008.34. The disclosure for this sale can be found here. Insiders sold a total of 231,838 shares of company stock worth $9,751,945 in the last three months. Company insiders own 16.50% of the company’s stock.

EBS has been the subject of several recent research reports. Wells Fargo & Co reaffirmed an “outperform” rating and issued a $43.00 price target (up previously from $41.00) on shares of Emergent Biosolutions in a report on Saturday, September 30th. Zacks Investment Research raised Emergent Biosolutions from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a report on Wednesday, October 25th. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $46.00.

Shares of Emergent Biosolutions Inc (NYSE:EBS) opened at $46.77 on Wednesday. Emergent Biosolutions Inc has a twelve month low of $27.94 and a twelve month high of $47.37. The firm has a market capitalization of $1,928.61, a price-to-earnings ratio of 27.67, a P/E/G ratio of 1.34 and a beta of 1.24. The company has a current ratio of 7.37, a quick ratio of 6.46 and a debt-to-equity ratio of 0.38.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported $0.73 EPS for the quarter, beating the Zacks’ consensus estimate of $0.41 by $0.32. The firm had revenue of $149.43 million for the quarter, compared to analyst estimates of $124.55 million. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period last year, the company earned $0.56 EPS. equities analysts anticipate that Emergent Biosolutions Inc will post 1.58 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.com-unik.info/2017/12/27/emergent-biosolutions-inc-ebs-shares-bought-by-legal-general-group-plc.html.

Emergent Biosolutions Profile

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Want to see what other hedge funds are holding EBS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Emergent Biosolutions Inc (NYSE:EBS).

Institutional Ownership by Quarter for Emergent Biosolutions (NYSE:EBS)

What are top analysts saying about Emergent Biosolutions? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Emergent Biosolutions and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit